Skip to main content
Fig. 4 | Acta Neuropathologica Communications

Fig. 4

From: Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results

Fig. 4

Driver mutation VAF, MGMTpromoter methylation scores, and tumor cellularity. (A) Linear regression of MGMT promoter pyrosequencing score versus driver mutation VAF for all glioma samples. (B) Linear regression of MGMT promoter pyrosequencing score versus TERT promoter mutation VAF for GBM. (C) Linear regression of MGMT promoter pyrosequencing score versus IDH mutation VAF for IDHmut astrocytoma. (D) Linear regression of MGMT promoter pyrosequencing score versus IDH mutation VAF for IDHmut oligodendroglioma. (E) Linear regression of microscopically estimated cellularity versus cellularity calculated from driver mutation VAF (2×VAF×100%) for all glioma samples. (F) Differences between microscopically estimated cellularity and cellularity calculated from VAF (Y-axis) plotted as a function of VAF (X-axis), for all glioma samples. (G) TERT promoter mutation VAF by ddPCR in high versus low cellularity areas of GBM tissue samples. (H) MGMT promoter methylation score by ddPCR in high versus low cellularity areas of GBM tissue samples (GBM: IDH-wildtype glioblastoma, IDHmut astrocytoma: IDH-mutant astrocytoma, IDHmut oligodendroglioma: IDH-mutant and 1p/19q co-deleted oligodendroglioma, pyroseq: pyrosequencing, ddPCR: droplet digital PCR)

Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us